AHASTAT: Valeant needs to keep its promises

An article yesterday in the New York Times highlights the yet-to-be-fulfilled promises made by Valeant Pharmaceuticals International to the U.S. Congress, AHA President and CEO Rick Pollack writes in an AHASTAT blog post today. “Valeant had said it would give hospitals discounts of as much as 30% on two of its expensive heart drugs [Nitropress and Isprel],” Pollack notes. “But those discounts never materialized and may have been disingenuous. New stories illustrating how hospitals and health systems are impacted by rising drug prices and the effect this has on the patients they serve continue to emerge… These unchecked drug price increases, as illustrated by the examples of Nitropress and Isprel, are unsustainable and a serious economic threat to the patients and communities served by America’s hospitals and health systems.”